Healthcare contract manufacturings: Increase in use of healthcare contract manufacturering for industrial purpose at a strong CAGR of 8.96% during the forecast period 2022-2030

Pune, India, 2022 /press release/- Market Research Future Published a Half Cooked Research Report on Global Healthcare contract manufacturing Market.

The global Healthcare Contract Manufacturing Market is expected to be valued at USD 507.12 Billion by 2030, growing at an 8.96% CAGR during forecast 2022-2030

Regional Analysis:

Global healthcare contract manufacturings consist of regions namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas holds the largest share of the global healthcare contract manufacturing market owing to the rising number of drug approvals as one of the factors fuelling the growth. The patent expiries of blockbuster drugs are creating a new opportunity to vendors to develop biosimilars at low cost. Thus, the market is anticipated entry of biosimilars and generics, which is likely to further strengthen the growth in this region.

The European market dominated the global healthcare contract manufacturings market owing to the high prevalence rate of various disease in the Eastern European regions.

The Asia Pacific region is anticipated to be the fastest growing region over the forecast period owing to the increasingly favorable government initiatives along with the improving healthcare infrastructure.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Healthcare Contract Manufacturing Market Research Report

Segmentation

The global healthcare contract manufacturing market is segmented on the basis of product, industry, type, and services.

On the basis of the product, the global healthcare contract manufacturing market is segmented into active pharmaceutical ingredients (API), final dosage formulations (FDF), advanced drug delivery products, OTC medicines and nutritional products, and others. Moreover, the finished dosage formulations (FDF) is segmented into a tablet, capsules, oral liquids, parenteral/injectables, and others.

On the basis of the industry, the global healthcare contract manufacturing market is segmented into pharmaceutical, biopharmaceutical, and others.

On the basis of the type, the global healthcare contract manufacturing market is segmented into sterile, non-sterile, and others

On the basis of the service, the global healthcare contract manufacturing market is segmented into oncology research, vaccines research, inflammation & immunology research, cardiology research, neuroscience research, and others.

Key Players

Some of key the players in the global healthcare contract manufacturings market are Patheon (Netherlands), Lonza (Switzerland), Evonik Industries (Germany), Teva Pharmaceutical Industries (Israel), Boehringer Ingelheim BioXcellence (Germany), Famar S.A. (Greece), Fareva Group (France), Vetter Pharma International (Germany), Mylan (U.S.), Recipharm (Sweden), Aesica Pharmaceuticals (U.K.), Althea Technologies (U.S.),  Aenova (Germany), Dishman Pharmaceuticals and Chemicals Limited (India), Catalent Pharma Solutions (U.S.), Kemwell Pvt. Ltd. (India), Jubilant Life Sciences Limited (India), Nipro Corporation (Japan), NextPharma (UK), Pfizer Central Source (U.S.), Royal DSM N.V. (Netherlands), Abbott Laboratories (U.S.), Amgen (U.S.), Apotex (U.S.), Aspen (U.S.), AstraZeneca PLC (UK), Aurobindo Pharma (India), Baxter International  (U.S.), BERLIN-CHEMIE (Germany), Biocon (India), Biogen (U.S.), Celltrion (South Korea),  Cipla (India), Coherus Biosciences (U.S.), Daiichi Sankyo (Japan), Dr. Reddy's Laboratories (India), Eli Lilly and Company (U.S.), Emcure Pharmaceuticals (India), Eurofarma Laboratories (Brazil), Gedeon Richter (Hungary), Gilead Sciences (U.S.), GlaxoSmithKline (GSK) Plc (U.S.), Hospira (U.S.), Impax Laboratories (U.S.), Intas Pharmaceuticals (India), Janssen Pharmaceuticals (U.S.), Lupin (India), Merck and Co. Inc. (U.S.), Mitsubishi Tanabe Pharma (Japan), Momenta Pharmaceuticals (U.S.), Natco Pharma (India), Nexus Pharmaceuticals (U.S.), Novo Nordisk (Denmark), Orchid Chemicals & Pharmaceuticals (India), Par Pharmaceutical (U.S.), Parenteral Drugs (India), Piramal (India), Roche Holding (Switerzland), Sanofi (France), Synthon (Netherlands), Teva Pharmaceuticals (Israel), Valeant Pharmaceuticals (Canada), Zentiva (Czech Republic), Zhejiang Huahai Pharmaceutical (China), Zydus Cadila (India), and others.